Vitreous -Retina- Macula Consultants of New York
12
0
0
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 90/100
41.7%
5 terminated/withdrawn out of 12 trials
50.0%
-36.5% vs industry average
17%
2 trials in Phase 3/4
40%
2 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Intense Treatment Regimen With Intravitreal Aflibercept Injection
Role: lead
To Evaluate The Role of Intravitreal Aflibercept Injection (2.0 mg) in the Management of Previously Treated Patients With Exudative AMD
Role: lead
Open Label to Study to Evaluate Effect of Alfilbercept on Patients With (FVPED) Fibrovascular Pigment Epithelial Detachment
Role: lead
A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study)
Role: lead
Second Line Therapy to Treat Age-related Macular Degeneration (AMD) for Patients Not Responding Well to Lucentis Therapy by Itself
Role: lead
Use of Eylea for the Treatment of an Optic Nerve Hemangioma
Role: lead
Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema
Role: lead
Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Role: lead
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
Role: collaborator
Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration
Role: lead
Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy
Role: lead
Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD
Role: lead
All 12 trials loaded